ANGLE’s Parsortix system advances cancer research

LONDON - ANGLE plc (AIM:AGL OTCQX:ANPCY), a leader in liquid biopsy technology, has been recognized for its role in facilitating significant cancer research through its Parsortix system, as detailed in three new peer-reviewed publications. The studies, published in reputable journals, showcase the system’s ability to enrich circulating tumor cells (CTCs) from blood samples, providing new insights into cancer biology and potential therapeutic targets.

One study, led by Professor Klaus Pantel at the University Medical (TASE:BLWV) Center Hamburg-Eppendorf, found that prostate cancer surgery can release both healthy and cancerous cells into the bloodstream. This discovery, published in the Journal of Experimental & Clinical Cancer Research, suggests that the Parsortix system could be vital in understanding and minimizing the spread of cancer during surgical procedures.

Similarly, research from Trinity College Dublin, headed by Professor John O’Leary, reported higher yields of CTCs from local tumor veins compared to peripheral veins during ovarian cancer surgery. Published in the European Journal of Surgical Oncology, the findings indicate that even early-stage patients might face the risk of tumor cell dissemination, emphasizing the importance of monitoring CTCs during surgery.

Furthermore, a study from the Cleveland Clinic, published in Cancers, investigated the gene expression of CTCs in breast cancer patients, revealing a mechanical conditioning score that correlates with metastatic potential. This work underscores the Parsortix system’s utility in gene expression analysis, which could guide the use of anti-fibrotic drugs in treatment.

These publications highlight the Parsortix system’s impact on oncology research, with potential implications for drug discovery and development. ANGLE’s technology has contributed to understanding CTC clusters, identifying new biomarkers, and exploring novel drug classes.

ANGLE’s Chief Scientific Officer, Karen Miller, expressed pride in the technology’s role in these breakthroughs, signaling a growing contribution to the oncology pipeline. With the Parsortix system’s ability to provide multiomic information from CTCs, the future of personalized cancer diagnostics and therapeutics looks promising.

The Parsortix system is an FDA-cleared, patented CTC harvesting technology that allows for comprehensive downstream analysis of blood samples, aiding in research, drug development, and clinical oncology.

This report is based on a press release statement from ANGLE plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.